The Centers for Medicare and Medicaid Services (CMS) has released preliminary 2027 payment rates for clinical diagnostic laboratory tests, signaling significant cuts to Medicare reimbursements. The agency found Medicare has been paying about 16% more for lab services than private insurers — and it's moving to close that gap, with estimated savings of $1 billion per year for taxpayers.

The American Clinical Laboratory Association (ACLA) pushed back hard, warning that the proposed cuts would reduce payments for nearly 1,200 tests and threaten patient access to critical diagnostics. The group also questioned the data behind the rates, noting they rely on information from just 2% of all Medicare Part B labs. Markets reacted swiftly — Quest Diagnostics fell nearly 5% and Labcorp dropped over 3% after the announcement.

By the Numbers:

• ~16% — how much more Medicare was paying vs. private insurers
• $1B — estimated annual taxpayer savings from the cuts
• 775 tests face the maximum 15% cut in 2027 alone
• Nearly 1,200 tests would see reduced payments overall
• Data used covers only 2% of Medicare Part B labs

Why it matters: These cuts follow years of payment freezes and prior reductions under PAMA, putting sustained financial pressure on clinical labs. If finalized in November, the changes could reshape lab economics, limit diagnostic investment, and ultimately affect patient access to testing — particularly in underserved areas.